Peer-reviewed article
Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol.
Chia XY, Cai J, Dai D, Ji Q, Liu S et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a protocol for a randomized controlled trial testing whether Tuina, a traditional Chinese manual therapy, can help children aged 6-14 years with combined allergic rhinitis and asthma syndrome. The study will compare 92 children receiving conventional medication alone against those receiving medication plus Tuina therapy delivered three times weekly for four weeks. The trial will measure improvements in quality of life, asthma control, and traditional Chinese medicine symptom scores, while monitoring for safety.
Key points
- Combined allergic rhinitis and asthma syndrome (CARAS) is a prevalent chronic respiratory disorder in children that substantially impairs quality of life
- Pediatric Tuina has shown potential in managing pediatric respiratory conditions but lacks sufficient evidence specifically for CARAS
- 92 children aged 6-14 years will be randomly assigned to conventional medication alone or medication plus Tuina therapy (3 times weekly for 4 weeks)
- Primary outcome is the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) score
- The study includes a 24-week follow-up period and systematic safety monitoring for adverse events
Limitations
This document is a protocol only and presents no actual results or findings. No data on efficacy, safety, or outcomes are yet available, and the trial has not been conducted, so the effectiveness of Tuina therapy for CARAS remains to be determined.
Abstract
Background Combined allergic rhinitis and asthma syndrome (CARAS) is a prevalent chronic respiratory disorder among children, characterized by the coexistence of allergic rhinitis and asthma symptoms, thereby substantially impairing quality of life. Pediatric Tuina, a traditional Chinese manual therapy, has demonstrated potential in the management of pediatric respiratory conditions; however, its effectiveness in treating CARAS remains insufficiently studied. Objective This trial aims to assess the clinical efficacy and safety of pediatric Tuina in the treatment of CARAS, with the objective of establishing an effective, safe, and convenient external therapy of traditional Chinese medicine for CARAS. Methods A total of 92 children aged 6-14 years with CARAS in remission will be randomly assigned (1:1) to either the control group (conventional medication) or the intervention group (conventional medication plus pediatric Tuina). The intervention will be administered three times weekly for 4 weeks, followed by a 24-week follow-up. The primary outcome measure is the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) score. Secondary outcomes include the Childhood Asthma Control Test (C-ACT) / Asthma Control Test (ACT) score and traditional Chinese medicine (TCM) symptom scores. Safety will be assessed by monitoring any adverse events during the treatment period. Discussion This study will provide evidence for the efficacy and safety of pediatric Tuina in improving CARAS symptoms and quality of life in children. Clinical trial registration https://itmctr.ccebtcm.org.cn/mgt/project/view/1966089236985806848, identifier [ITMCTR2025001712].
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Pediatric Tuina (traditional Chinese manual therapy) administered three times weekly for 4 weeks, plus conventional medication
- Population
- Children aged 6-14 years with combined allergic rhinitis and asthma syndrome in remission (n=92, randomized 1:1)
Key finding
This is a protocol document; no outcomes or findings are reported as the trial has not yet been conducted